BioCentury | Dec 11, 2019
Financial News

Local demand high for Alphamab Oncology’s Hong Kong IPO

...Co. Ltd. (HKEX:2616), CanSino Biologics Inc. (HKEX:6185), Mabpharm Ltd. (HKEX:2181), Shanghai Henlius Biotech Inc. (HKEX:2696), Tot Biopharm Co. Ltd....
BioCentury | Nov 9, 2019
Financial News

Nov. 8 Financial Quick Takes: First day of trading for BrightGene, Tot; plus argenx, Agios and AiCure

...immuno-oncology agents, antibody-drug conjugates for solid tumors and other tumor-targeting drug conjugates for brain cancer. Tot Biopharm Co. Ltd....
...response. Targets: GLP-1R (GLP1R) - Glucagon-like peptide-1 receptor Hongjiang Li, Staff Writer and Paul Bonanos, Associate Editor Tot Biopharm Co. Ltd. BrightGene...
BioCentury | Nov 7, 2019
Financial News

More weakness among IPOs as Galera, Centogene limp into marketplace

...the Hong Kong stock exchange’s biotech chapter have resumed after a lull, with cancer company Tot Biopharm...
...2020 U.S. election year (see “Flood of IPOs Expected” ). Hong Kong window On Thursday, Tot Biopharm Co. Ltd....
...TAB008, a biosimilar of Avastin bevacizumab from Roche (SIX:ROG; OTCQX:RHHBY). Paul Bonanos, Associate Editor Galera Therapeutics Inc. 89bio Inc. IPOs Tot Biopharm Co. Ltd....
BioCentury | Nov 1, 2019
Financial News

Nov. 1 Financial Quick Takes: Kira raises $13.8M series A; plus SinoMab, Tot, Shasqi and Sense Biodetection

...CICC, Orient, China Everbright, Guotai Junan, CMB International, Haitong International, Fosun Hani and Victory. Suzhou-based Tot Biopharm Co. Ltd....
...to move its unnamed localized chemotherapy into a Phase I trial in 2Q20. Hongjiang Li, Staff Writer Tot Biopharm Co. Ltd. SinoMab...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...Co. Ltd. (Shanghai) 6/10/19 TBD Ph III Inhibrx Inc. 6/3/19 Up to $74.8 Ph I Tot Biopharm Co. Ltd....
BioCentury | Sep 18, 2019
Financial News

Hong Kong’s first IPO in months values Shanghai Henlius at $3.4B

...Ltd., Venus Medtech (Hangzhou) Inc., Alphamab Oncology Ltd., SinoMab BioScience Ltd., Tasly Biopharmaceuticals Co. Ltd., Tot Biopharm...
BioCentury | Jul 20, 2019
Emerging Company Profile

China Ophthalmology Focus eyes Asia market

...collaborators: Hong Kong Polytechnic University, Sun Yat-Sen University Corporate partners: Kato Pharmaceuticals, RegeneRx Biopharmaceuticals Inc., Tot Biopharm Co. Ltd....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...Inhibrx Inc. 6/3/19 Up to $74.8 Ph I Dermavant Sciences Ltd. 5/24/19 $100.1 Ph III Tot Biopharm Co. Ltd....
BioCentury | May 8, 2019
Financial News

CRO Viva raises $193.9 million in Hong Kong IPO

...Shanghai, China), MicuRx Pharmaceuticals Inc. (Foster City, Calif), Ascentage Pharma Group International (Suzhou, China) and Tot Biopharm Co. Ltd....
BioCentury | Apr 30, 2019
Financial News

April 30 Financial Quick Takes: Mustang, Tot Biopharm, Axcella and more

...Therapy Produces Functional Immunity in SCID-X1 Patients" ). Tot looking to list in Hong Kong Tot Biopharm Co. Ltd....
...led the newco’s undisclosed series A round. Elizabeth S. Eaton, Staff Writer Axcella Health Inc. Congenica Ltd. Mustang Bio Inc. Tot Biopharm Co. Ltd. Nimble...
Items per page:
1 - 10 of 14
BioCentury | Dec 11, 2019
Financial News

Local demand high for Alphamab Oncology’s Hong Kong IPO

...Co. Ltd. (HKEX:2616), CanSino Biologics Inc. (HKEX:6185), Mabpharm Ltd. (HKEX:2181), Shanghai Henlius Biotech Inc. (HKEX:2696), Tot Biopharm Co. Ltd....
BioCentury | Nov 9, 2019
Financial News

Nov. 8 Financial Quick Takes: First day of trading for BrightGene, Tot; plus argenx, Agios and AiCure

...immuno-oncology agents, antibody-drug conjugates for solid tumors and other tumor-targeting drug conjugates for brain cancer. Tot Biopharm Co. Ltd....
...response. Targets: GLP-1R (GLP1R) - Glucagon-like peptide-1 receptor Hongjiang Li, Staff Writer and Paul Bonanos, Associate Editor Tot Biopharm Co. Ltd. BrightGene...
BioCentury | Nov 7, 2019
Financial News

More weakness among IPOs as Galera, Centogene limp into marketplace

...the Hong Kong stock exchange’s biotech chapter have resumed after a lull, with cancer company Tot Biopharm...
...2020 U.S. election year (see “Flood of IPOs Expected” ). Hong Kong window On Thursday, Tot Biopharm Co. Ltd....
...TAB008, a biosimilar of Avastin bevacizumab from Roche (SIX:ROG; OTCQX:RHHBY). Paul Bonanos, Associate Editor Galera Therapeutics Inc. 89bio Inc. IPOs Tot Biopharm Co. Ltd....
BioCentury | Nov 1, 2019
Financial News

Nov. 1 Financial Quick Takes: Kira raises $13.8M series A; plus SinoMab, Tot, Shasqi and Sense Biodetection

...CICC, Orient, China Everbright, Guotai Junan, CMB International, Haitong International, Fosun Hani and Victory. Suzhou-based Tot Biopharm Co. Ltd....
...to move its unnamed localized chemotherapy into a Phase I trial in 2Q20. Hongjiang Li, Staff Writer Tot Biopharm Co. Ltd. SinoMab...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...Co. Ltd. (Shanghai) 6/10/19 TBD Ph III Inhibrx Inc. 6/3/19 Up to $74.8 Ph I Tot Biopharm Co. Ltd....
BioCentury | Sep 18, 2019
Financial News

Hong Kong’s first IPO in months values Shanghai Henlius at $3.4B

...Ltd., Venus Medtech (Hangzhou) Inc., Alphamab Oncology Ltd., SinoMab BioScience Ltd., Tasly Biopharmaceuticals Co. Ltd., Tot Biopharm...
BioCentury | Jul 20, 2019
Emerging Company Profile

China Ophthalmology Focus eyes Asia market

...collaborators: Hong Kong Polytechnic University, Sun Yat-Sen University Corporate partners: Kato Pharmaceuticals, RegeneRx Biopharmaceuticals Inc., Tot Biopharm Co. Ltd....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...Inhibrx Inc. 6/3/19 Up to $74.8 Ph I Dermavant Sciences Ltd. 5/24/19 $100.1 Ph III Tot Biopharm Co. Ltd....
BioCentury | May 8, 2019
Financial News

CRO Viva raises $193.9 million in Hong Kong IPO

...Shanghai, China), MicuRx Pharmaceuticals Inc. (Foster City, Calif), Ascentage Pharma Group International (Suzhou, China) and Tot Biopharm Co. Ltd....
BioCentury | Apr 30, 2019
Financial News

April 30 Financial Quick Takes: Mustang, Tot Biopharm, Axcella and more

...Therapy Produces Functional Immunity in SCID-X1 Patients" ). Tot looking to list in Hong Kong Tot Biopharm Co. Ltd....
...led the newco’s undisclosed series A round. Elizabeth S. Eaton, Staff Writer Axcella Health Inc. Congenica Ltd. Mustang Bio Inc. Tot Biopharm Co. Ltd. Nimble...
Items per page:
1 - 10 of 14